Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer
NCT00326495Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2006
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in colorectal cancer (CRC), sponsored by National Cancer Institute. Started May 2006; status: completed.
02
Drugs
sorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00326495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00326495.